Huma Therapeutics Ltd.

https://www.huma.com

LinkedIn: https://www.linkedin.com/company/humaforhealth

Huma is a global healthcare AI company on a mission to accelerate the adoption of digital solutions in care and research. Its award-winning modular platforms are used by more than 3,000 hospitals and clinics, with over 35 million screened users and 4 million registered users in healthcare, and has powered over 800 studies supporting about 1 million participants across research. The company is renowned for its role in major national healthcare projects worldwide, from the US and the UK to Germany, Greece, and Saudi Arabia, as well as collaborating with most large pharma companies. Huma's technology powers: > multi-channel patient engagement at population-wide scale for healthcare systems > remote patient monitoring (RPM) at scale > companion apps to support patients through treatment and drug therapies > digital clinical trials, including decentralised trials, to accelerate medical research Huma's regulated Software as a Medical Device, used in its RPM and companion app platforms, is the only disease- and device- agnostic platform to hold EU MDR Class IIb, US FDA (510-k) Class II clearance and Class IIb registration with the UK MHRA. The SaMD platform is regulated to accept artificial intelligence algorithms and monitor patients of all ages. *

	Start	2021-12-27 existent
	Group	Huma Therapeutics (Group)
	Predecessor	MedoPad Ltd.
	Industry	AI-based drug discovery / AI-based drug development
	Industry 2	artificial intelligence (AI) / machine learning (ML)
	Person	Vahdat, Dan (Huma Therapeutics 202407 CEO + Founder)

	Street	21-24 Millbank Millbank Tower
	City	SW1P 4QP London
		Address record changed: 2024-07-20

Basic data	Employees	D: 101 to 500 (2024-07-19)

		* Document for »About Section«: Huma Therapeutics Ltd.. (7/16/24). "Press Release: Huma Completes Series D with Total Financing of over $80m as It Launches Huma Cloud Platform with GenAI Integrations to Bring Digital First Care and Research to Everyone". London & New York, NY.

		Record changed: 2025-03-16

Picture biomindz TRON LSE Mainz Translation Cancer Immunotherapy 650x200px

More documents for Huma Therapeutics (Group)

[1] Huma Therapeutics Ltd.. (7/16/24). "Press Release: Huma Completes Series D with Total Financing of over $80m as It Launches Huma Cloud Platform with GenAI Integrations to Bring Digital First Care and Research to Everyone". London & New York, NY....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]